GO:1903945 positive regulation of hepatocyte apoptotic process: Signaling Pathways, Genes, Functions and Research Methods
Research-grade guide for scientists and biopharma professionals
Key Takeaways
• GO:1903945 describes any process that activates or increases the frequency, rate or extent of hepatocyte apoptosis, a form of programmed cell death in liver parenchymal cells.
• Dysregulated hepatocyte apoptosis is a central driver of nonalcoholic steatohepatitis (NASH), acute liver failure, ischemia/reperfusion injury, and alcohol-associated liver disease.
• Key molecular axes include p-STAT3/ANXA2/caspase-1 pyroptosis, MKK4/JNK stress signaling, ERRγ-CYP2E1 oxidative stress, and PDCD4/MHC-II immune activation.
• The process is regulated by a balance of pro-apoptotic and pro-survival signals, including cytokines, oxidative stress, ER stress, and metabolic cues.
• CRISPR-based knockout, point mutation, knock-in, and overexpression models enable causal dissection of genes that positively regulate hepatocyte apoptosis.
• Therapeutic strategies that inhibit hepatocyte apoptosis, such as polydatin, fluorofenidone, and FGF4, show protective effects in preclinical liver disease models.
Description
Positive regulation of hepatocyte apoptotic process (GO:1903945) is a biological process term that encompasses all molecular events that activate or increase the frequency, rate, or extent of apoptosis specifically in hepatocytes, the primary functional cells of the liver. Hepatocyte apoptosis is a tightly controlled form of programmed cell death essential for liver homeostasis, but its excessive activation contributes to a wide spectrum of acute and chronic liver diseases, including nonalcoholic steatohepatitis (NASH), alcohol-associated liver injury, ischemia/reperfusion injury, and acute liver failure. Understanding the positive regulators of this process is therefore critical for identifying therapeutic targets and biomarkers. Recent studies have elucidated several signaling axes that promote hepatocyte apoptosis, such as the p-STAT3/ANXA2/caspase-1 pyroptosis pathway in NASH, the MKK4/JNK stress kinase cascade in acute liver failure, and the ERRγ-CYP2E1 oxidative stress axis in alcohol-associated liver injury. These pathways converge on mitochondrial dysfunction, caspase activation, and inflammatory signaling, making them attractive nodes for pharmacological intervention. This article synthesizes current knowledge on the mechanisms, key genes, disease relevance, and research methodologies for studying GO:1903945, with a focus on CRISPR-based functional genomics approaches.
positive regulation of hepatocyte apoptotic process At A Glance
| GO ID | GO:1903945 |
|---|---|
| GO term | positive regulation of hepatocyte apoptotic process |
| Ontology | biological_process |
| Synonym | activation of hepatocyte apoptosis; upregulation of hepatocyte apoptotic process; positive regulation of hepatocyte apoptosis |
| Major function | Activation or increase of the frequency, rate or extent of apoptosis in hepatocytes |
| Related processes | Hepatocyte apoptosis, pyroptosis, JNK signaling, oxidative stress response, inflammatory signaling |
| Disease relevance | NASH, acute liver failure, alcohol-associated liver injury, hepatic ischemia/reperfusion injury, hepatocellular carcinoma |
| Key regulators | STAT3, ANXA2, MKK4, JNK, ERRγ, CYP2E1, PDCD4, FGF4 |
| Research methods | CRISPR knockout/knock-in, RNA-seq, proteomics, flow cytometry, TUNEL assay, caspase activity assays |
What Is GO:1903945?
GO:1903945, positive regulation of hepatocyte apoptotic process, is defined as any process that activates or increases the frequency, rate or extent of hepatocyte apoptotic process. In practical terms, it includes molecular signals, signaling cascades, and cellular stressors that promote the initiation or execution of apoptosis in hepatocytes, such as death receptor activation, mitochondrial outer membrane permeabilization, caspase activation, and inflammatory cell death pathways like pyroptosis when they intersect with apoptotic machinery.
Why Is positive regulation of hepatocyte apoptotic process Important in Cell Biology?
Hepatocyte apoptosis is a double-edged sword: while it is essential for removing damaged cells and maintaining liver homeostasis, its excessive activation drives the pathogenesis of major liver diseases. Positive regulators of hepatocyte apoptosis are therefore high-value targets for therapeutic intervention. For example, inhibition of the MKK4/JNK pathway by fluorofenidone protects against acute liver failure in mice, and repression of the ERRγ-CYP2E1 pathway by FGF4 mitigates alcohol-associated liver injury. In NASH, the p-STAT3/ANXA2 axis promotes caspase-1-mediated hepatocyte pyroptosis, and its blockade reduces liver injury. PDCD4 deficiency in hepatocytes exacerbates NASH through enhanced MHC class II transactivator expression, highlighting the role of immune-apoptosis crosstalk. Understanding GO:1903945 is thus critical for developing targeted therapies for liver diseases.
• Hepatocyte apoptosis is a hallmark of nonalcoholic steatohepatitis (NASH) and drives fibrosis progression.
• Excessive hepatocyte apoptosis contributes to acute liver failure and ischemia/reperfusion injury.
• Alcohol-associated liver injury involves oxidative stress-mediated hepatocyte apoptosis via the ERRγ-CYP2E1 pathway.
• The p-STAT3/ANXA2/caspase-1 axis links inflammation to hepatocyte pyroptosis in NASH.
• PDCD4 deficiency in hepatocytes promotes NASH through MHC class II transactivator expression.
• Therapeutic inhibition of hepatocyte apoptosis (e.g., by polydatin or fluorofenidone) protects against liver injury in preclinical models.
• Hepatocyte apoptosis modulates the tumor microenvironment and immune surveillance in hepatocellular carcinoma.
• CRISPR screening can identify novel positive regulators of hepatocyte apoptosis for drug target discovery.
• Biomarkers of hepatocyte apoptosis (e.g., caspase-cleaved cytokeratin-18) are used in clinical trials for NASH.
• Understanding species-specific differences in hepatocyte apoptosis regulation is essential for translating preclinical findings.
What Happens During positive regulation of hepatocyte apoptotic process?
Initiation by Death Receptor and Stress Signaling
In simple terms: The process starts when external or internal stress signals tell the hepatocyte to die.
Positive regulation of hepatocyte apoptosis can be initiated by extrinsic death receptor ligands (e.g., TNF-α, FasL, TRAIL) or intrinsic stressors such as oxidative stress, ER stress, and DNA damage. In NASH, the p-STAT3/ANXA2 axis promotes caspase-1-mediated hepatocyte pyroptosis, a form of inflammatory cell death that intersects with apoptotic signaling. In alcohol-associated liver injury, the ERRγ-CYP2E1 pathway generates reactive oxygen species that trigger hepatocyte apoptosis. The MKK4/JNK stress kinase cascade is activated in acute liver failure and promotes hepatocyte death. These initiation events converge on mitochondrial dysfunction and caspase activation.
Mitochondrial Outer Membrane Permeabilization and Caspase Activation
In simple terms: The cell's power plants leak death signals that activate executioner enzymes.
Following initiation, pro-apoptotic Bcl-2 family proteins (e.g., Bax, Bak) permeabilize the mitochondrial outer membrane, leading to cytochrome c release and apoptosome formation. This activates caspase-9 and downstream executioner caspases-3 and -7. In hepatocytes, this intrinsic pathway is a key node positively regulated by JNK signaling, which can phosphorylate and inactivate anti-apoptotic Bcl-2 proteins. The p-STAT3/ANXA2 axis also promotes caspase-1 activation, which can cleave gasdermin D and induce pyroptosis, a lytic form of cell death that shares features with apoptosis.
Inflammatory Crosstalk and Immune Cell Recruitment
In simple terms: Dying liver cells call in immune cells, which can make the damage worse.
Hepatocyte apoptosis releases damage-associated molecular patterns (DAMPs) that activate Kupffer cells and recruit immune cells, amplifying liver injury. In NASH, PDCD4 deficiency in hepatocytes enhances MHC class II transactivator expression, promoting antigen presentation and T cell activation that exacerbates inflammation and apoptosis. Tumor-induced splenic erythroblast-like Ter-cells promote tumor progression in hepatocellular carcinoma, partly by modulating the immune microenvironment. This crosstalk creates a feed-forward loop of hepatocyte death and inflammation.
Resolution or Progression to Fibrosis and Cirrhosis
In simple terms: If the death signals stop, the liver can heal; if not, scarring and liver failure follow.
Acute hepatocyte apoptosis can resolve if the trigger is removed, but chronic apoptosis drives stellate cell activation and fibrosis. In diet-induced NASH, polydatin attenuates hepatocyte apoptosis and fibrosis in mice. Persistent activation of the MKK4/JNK pathway in acute liver failure leads to massive hepatocyte death and liver failure. The balance between pro-survival (e.g., FGF4-mediated repression of ERRγ-CYP2E1) and pro-apoptotic signals determines disease outcome.
Key Genes Involved in GO:1903945 positive regulation of hepatocyte apoptotic process
The following genes and proteins have been experimentally implicated in the positive regulation of hepatocyte apoptotic process, based on the verified literature.
| Gene | Major Role | Research Relevance |
|---|---|---|
| STAT3 | Phosphorylated STAT3 (p-STAT3) promotes ANXA2 expression and caspase-1-mediated pyroptosis in NASH | Target for NASH therapy; p-STAT3/ANXA2 axis is a key positive regulator |
| ANXA2 | Mediates caspase-1 activation and hepatocyte pyroptosis downstream of p-STAT3 | Biomarker and therapeutic target in NASH |
| CASP1 | Caspase-1 cleaves gasdermin D and IL-1β, promoting pyroptosis and inflammation | Central to inflammatory hepatocyte death in NASH |
| MKK4 | Stress kinase that activates JNK and promotes hepatocyte apoptosis in acute liver failure | Target of fluorofenidone; inhibition protects against liver failure |
| JNK | Phosphorylates Bcl-2 family proteins and promotes mitochondrial apoptosis | Key effector of hepatocyte death; inhibited by fluorofenidone |
| ERRγ | Orphan nuclear receptor that upregulates CYP2E1 and oxidative stress in alcohol-associated liver injury | Repressed by FGF4; target for alcohol-associated liver disease |
| CYP2E1 | Cytochrome P450 enzyme that generates reactive oxygen species and promotes hepatocyte apoptosis | Downstream of ERRγ; mediates alcohol-induced oxidative stress |
| FGF4 | Growth factor that represses ERRγ-CYP2E1 pathway and protects against alcohol-associated liver injury | Potential therapeutic agent for alcohol-associated liver disease |
| PDCD4 | Pro-apoptotic protein; deficiency in hepatocytes exacerbates NASH via MHC class II transactivator | Tumor suppressor and regulator of inflammation-apoptosis crosstalk |
| MHC-II | Major histocompatibility complex class II; upregulated by PDCD4 deficiency, promotes T cell activation | Links hepatocyte apoptosis to adaptive immunity in NASH |
| GPC3 | Glypican 3; target of CAR T cells that eliminate hepatocellular carcinoma cells | Immunotherapy target; CAR T cells induce apoptosis in GPC3+ HCC |
| SNHG1 | Long non-coding RNA; SNHG1-miR-186-5p-YY1 feedback loop alleviates hepatic ischemia/reperfusion injury | Regulates hepatocyte apoptosis in ischemia/reperfusion injury |
| YY1 | Transcription factor; part of SNHG1-miR-186-5p-YY1 feedback loop | Modulates hepatocyte survival in ischemia/reperfusion injury |
| miR-186-5p | MicroRNA; targets YY1 and regulates hepatocyte apoptosis in ischemia/reperfusion injury | Potential therapeutic target for liver ischemia/reperfusion injury |
| Ter-cells | Tumor-induced splenic erythroblast-like cells that promote tumor progression | Modulate immune microenvironment in hepatocellular carcinoma |
| Polydatin | Natural compound that attenuates diet-induced NASH and fibrosis by inhibiting hepatocyte apoptosis | Preclinical therapeutic for NASH |
| Fluorofenidone | Antifibrotic agent that protects against acute liver failure by regulating MKK4/JNK pathway | Preclinical therapeutic for acute liver failure |
How Is positive regulation of hepatocyte apoptotic process Regulated?
The positive regulation of hepatocyte apoptotic process is controlled by a complex network of signaling pathways. The p-STAT3/ANXA2 axis is activated by inflammatory cytokines in NASH and promotes caspase-1-mediated pyroptosis. The MKK4/JNK stress kinase pathway is activated by oxidative stress and cytokines in acute liver failure, and its inhibition by fluorofenidone reduces hepatocyte apoptosis. The ERRγ-CYP2E1 pathway is repressed by FGF4, which mitigates alcohol-associated liver injury by reducing oxidative stress and apoptosis. PDCD4 deficiency in hepatocytes enhances MHC class II transactivator expression, promoting immune-mediated liver injury in NASH. The SNHG1-miR-186-5p-YY1 feedback loop alleviates hepatic ischemia/reperfusion injury by modulating hepatocyte apoptosis. These regulatory mechanisms offer multiple entry points for therapeutic intervention.
positive regulation of hepatocyte apoptotic process and Human Disease
| Gene | Disease / Biology | Potential Experimental Model |
|---|---|---|
| STAT3/ANXA2 | NASH; caspase-1-mediated pyroptosis | Hepatocyte-specific STAT3 or ANXA2 knockout mice fed a NASH diet |
| MKK4/JNK | Acute liver failure; stress kinase signaling | MKK4 or JNK knockout mice treated with hepatotoxic agents |
| ERRγ/CYP2E1 | Alcohol-associated liver injury; oxidative stress | Hepatocyte-specific ERRγ or CYP2E1 knockout mice fed an alcohol diet |
| PDCD4 | NASH; immune-mediated liver injury | Hepatocyte-specific PDCD4 knockout mice fed a NASH diet |
| GPC3 | Hepatocellular carcinoma; CAR T cell therapy | GPC3 knockout HCC cell lines and xenograft models |
Nonalcoholic Steatohepatitis (NASH)
NASH is characterized by hepatocyte apoptosis, inflammation, and fibrosis. The p-STAT3/ANXA2 axis promotes caspase-1-mediated hepatocyte pyroptosis in NASH, and its inhibition reduces liver injury. Polydatin attenuates diet-induced NASH and fibrosis in mice by inhibiting hepatocyte apoptosis. PDCD4 deficiency in hepatocytes exacerbates NASH through enhanced MHC class II transactivator expression, linking apoptosis to adaptive immunity. These findings highlight positive regulators of hepatocyte apoptosis as therapeutic targets in NASH.
Acute Liver Failure and Ischemia/Reperfusion Injury
Acute liver failure is driven by massive hepatocyte apoptosis and necrosis. The MKK4/JNK pathway is a key positive regulator, and fluorofenidone protects against acute liver failure in mice by inhibiting this pathway. Hepatic ischemia/reperfusion injury, a common complication of liver surgery, involves hepatocyte apoptosis regulated by the SNHG1-miR-186-5p-YY1 feedback loop. Targeting these pathways may reduce liver damage in clinical settings.
Alcohol-Associated Liver Disease
Alcohol-associated liver injury involves oxidative stress-mediated hepatocyte apoptosis. The ERRγ-CYP2E1 pathway promotes reactive oxygen species generation and hepatocyte death, and its repression by FGF4 mitigates alcohol-associated liver injury in preclinical models. This axis represents a promising therapeutic target for alcohol-associated liver disease.
Hepatocellular Carcinoma (HCC)
Hepatocyte apoptosis is a double-edged sword in HCC: it can eliminate tumor cells but also promote tumor-promoting inflammation. Glypican 3 (GPC3)-targeted CAR T cells eliminate orthotopic hepatocellular carcinomas in mice by inducing apoptosis. Tumor-induced splenic erythroblast-like Ter-cells promote tumor progression, partly by modulating the immune microenvironment. Understanding the positive regulation of hepatocyte apoptosis in HCC is critical for optimizing immunotherapy.
From positive regulation of hepatocyte apoptotic process-Related Genes to Experimental Models
| Research Question | Suitable Model |
|---|---|
| Does gene X causally promote hepatocyte apoptosis in NASH? | Hepatocyte-specific knockout of gene X in mice fed a NASH diet |
| Does a point mutation in gene Y alter its pro-apoptotic function? | CRISPR knock-in of the point mutation in hepatocyte cell lines or mice |
| Does overexpression of gene Z exacerbate alcohol-associated liver injury? | Hepatocyte-specific overexpression of gene Z via AAV or transgenic mice |
| Can a tagged version of protein W track its localization during apoptosis? | Knock-in of a fluorescent or epitope tag at the endogenous locus |
| Which genes are essential for hepatocyte apoptosis in HCC? | Genome-wide CRISPR knockout library screening in HCC cell lines |
| Does a candidate drug inhibit hepatocyte apoptosis in vivo? | Mouse models of acute liver failure or NASH treated with the drug |
How to Study the positive regulation of hepatocyte apoptotic process Process
| Method | What It Measures | Typical Application |
|---|---|---|
| CRISPR knockout | Loss-of-function of a candidate gene | Determine if a gene is required for hepatocyte apoptosis |
| CRISPR knock-in | Introduction of specific point mutations or tags | Study disease-associated variants or track protein localization |
| RNA-seq | Global transcriptomic changes | Identify pathways upregulated during hepatocyte apoptosis |
| Proteomics | Protein expression and post-translational modifications | Discover novel regulators and biomarkers |
| TUNEL assay | DNA fragmentation as a marker of apoptosis | Quantify hepatocyte apoptosis in liver sections |
| Caspase activity assay | Enzymatic activity of caspase-3/7 or caspase-1 | Measure apoptotic or pyroptotic execution |
| Flow cytometry | Annexin V/PI staining for apoptotic cells | Quantify apoptosis in isolated hepatocytes |
| Immunohistochemistry | Protein localization and expression in tissue | Assess pathway activation in liver biopsies |
CRISPR-Based Functional Genomics
CRISPR knockout, point mutation, knock-in, and overexpression models enable causal interrogation of genes that positively regulate hepatocyte apoptosis. For example, hepatocyte-specific knockout of PDCD4 exacerbates NASH in mice, demonstrating its role in regulating apoptosis and inflammation. Genome-wide CRISPR screens can identify novel positive regulators of hepatocyte apoptosis in HCC cell lines.
Transcriptomic and Proteomic Profiling
RNA-seq and proteomics can reveal global changes in gene expression and protein abundance during hepatocyte apoptosis. In NASH models, the p-STAT3/ANXA2 axis was identified through molecular profiling. Proteomic analysis of liver tissues from alcohol-fed mice revealed upregulation of ERRγ-CYP2E1 pathway components. These methods help identify biomarkers and therapeutic targets.
Apoptosis Assays and Imaging
TUNEL staining, caspase-3/7 activity assays, and flow cytometry with Annexin V/PI staining are standard methods to quantify hepatocyte apoptosis. In acute liver failure models, fluorofenidone treatment reduced TUNEL-positive hepatocytes and caspase activity. Live-cell imaging of fluorescently tagged proteins can track mitochondrial permeabilization and caspase activation in real time.
In Vivo Liver Disease Models
Mouse models of NASH (diet-induced), acute liver failure (e.g., acetaminophen or LPS/D-galactosamine), alcohol-associated liver injury (chronic-plus-binge ethanol), and ischemia/reperfusion injury are essential for studying positive regulation of hepatocyte apoptosis. Polydatin was tested in diet-induced NASH mice, and FGF4 was tested in alcohol-fed mice. These models allow evaluation of genetic and pharmacological interventions.
How CRISPR Can Be Used to Study GO:1903945 positive regulation of hepatocyte apoptotic process
Knockout
CRISPR knockout of positive regulators of hepatocyte apoptosis (e.g., STAT3, ANXA2, MKK4, PDCD4) in hepatocyte cell lines or mice can determine whether they are causally required for apoptosis. For example, hepatocyte-specific PDCD4 knockout exacerbates NASH in mice, confirming its role in regulating apoptosis and inflammation. Knockout of MKK4 or JNK would test their requirement in acute liver failure models.
Point Mutation
CRISPR point mutation can introduce disease-associated variants or phospho-dead/phospho-mimetic mutations to dissect signaling mechanisms. For instance, mutating the phosphorylation site in STAT3 or ANXA2 could reveal how p-STAT3/ANXA2 axis promotes caspase-1-mediated pyroptosis. Point mutations in CYP2E1 could alter its enzymatic activity and oxidative stress generation.
Knock-in
CRISPR knock-in of fluorescent tags (e.g., GFP, mCherry) or epitope tags at endogenous loci enables real-time tracking of proteins during hepatocyte apoptosis. Tagging ANXA2 or caspase-1 would allow live-cell imaging of pyroptosis. Knock-in of reporter genes under the control of apoptosis-related promoters can create sensitive biosensors for high-throughput screening.
Overexpression
CRISPR activation (CRISPRa) or viral overexpression of candidate genes can test whether increased expression is sufficient to promote hepatocyte apoptosis. Overexpression of ERRγ or CYP2E1 in hepatocytes would be expected to exacerbate alcohol-associated liver injury. Overexpression of PDCD4 could sensitize hepatocytes to apoptosis in NASH models.
How EDITGENE Supports positive regulation of hepatocyte apoptotic process Research
Researchers studying positive regulation of hepatocyte apoptotic process-related genes often need to determine whether a candidate gene is causally involved in hepatocyte death, and whether its modulation can protect against liver disease. EDITGENE provides end-to-end CRISPR services to accelerate this research.
Contact EDITGENE today to design your custom CRISPR model for positive regulation of hepatocyte apoptotic process research.
Frequently Asked Questions About positive regulation of hepatocyte apoptotic process
What is GO:1903945?
GO:1903945 is the Gene Ontology term for positive regulation of hepatocyte apoptotic process, defined as any process that activates or increases the frequency, rate or extent of apoptosis in hepatocytes.
What genes are involved in positive regulation of hepatocyte apoptotic process?
Key genes include STAT3, ANXA2, CASP1, MKK4, JNK, ERRγ, CYP2E1, FGF4, PDCD4, MHC-II, GPC3, SNHG1, YY1, and miR-186-5p, as identified in NASH, acute liver failure, alcohol-associated liver injury, and HCC studies.
How is hepatocyte apoptosis regulated in NASH?
In NASH, the p-STAT3/ANXA2 axis promotes caspase-1-mediated pyroptosis, and PDCD4 deficiency enhances MHC class II transactivator expression, exacerbating liver injury.
What is the role of MKK4/JNK pathway in hepatocyte apoptosis?
The MKK4/JNK stress kinase pathway promotes hepatocyte apoptosis in acute liver failure, and its inhibition by fluorofenidone protects against liver injury in mice.
How does alcohol cause hepatocyte apoptosis?
Alcohol induces the ERRγ-CYP2E1 pathway, which generates reactive oxygen species and triggers hepatocyte apoptosis; FGF4 represses this pathway and mitigates liver injury.
Can CRISPR be used to study hepatocyte apoptosis?
Yes, CRISPR knockout, knock-in, point mutation, and overexpression models enable causal dissection of genes that regulate hepatocyte apoptosis, as demonstrated for PDCD4 and other targets.
What are the therapeutic targets for inhibiting hepatocyte apoptosis?
Potential targets include STAT3, ANXA2, MKK4, JNK, ERRγ, CYP2E1, and PDCD4. Compounds like polydatin and fluorofenidone show protective effects in preclinical models.
How is hepatocyte apoptosis measured?
Common methods include TUNEL assay, caspase-3/7 activity assays, Annexin V/PI flow cytometry, and immunohistochemistry for cleaved caspase-3.
What is the link between hepatocyte apoptosis and hepatocellular carcinoma?
Hepatocyte apoptosis can eliminate tumor cells but also promote tumor-promoting inflammation; GPC3-targeted CAR T cells induce apoptosis in HCC, and Ter-cells modulate the immune microenvironment.
What models are used to study positive regulation of hepatocyte apoptotic process?
Mouse models of NASH, acute liver failure, alcohol-associated liver injury, and ischemia/reperfusion injury, as well as hepatocyte cell lines and primary hepatocytes, are commonly used.
Conclusion
Positive regulation of hepatocyte apoptotic process (GO:1903945) is a critical biological process that underlies the pathogenesis of major liver diseases, including NASH, acute liver failure, alcohol-associated liver injury, and hepatocellular carcinoma. The identification of key molecular axes such as p-STAT3/ANXA2/caspase-1, MKK4/JNK, ERRγ-CYP2E1, and PDCD4/MHC-II has provided promising therapeutic targets, with compounds like polydatin and fluorofenidone showing efficacy in preclinical models. CRISPR-based functional genomics, combined with transcriptomics, proteomics, and in vivo disease models, offers a powerful toolkit to dissect these pathways and discover new regulators. Continued research into the positive regulation of hepatocyte apoptosis will likely yield novel strategies for treating liver diseases.
References
- 1. Li R et al.. 2018. Polydatin attenuates diet-induced nonalcoholic steatohepatitis and fibrosis in mice.. Int J Biol Sci 14(11):1411-1425 PMID: 30262993
- 2. Feng Y et al.. 2022. The p-STAT3/ANXA2 axis promotes caspase-1-mediated hepatocyte pyroptosis in non-alcoholic steatohepatitis.. J Transl Med 20(1):497 PMID: 36324154
- 3. Li D et al.. 2020. Persistent Polyfunctional Chimeric Antigen Receptor T Cells That Target Glypican 3 Eliminate Orthotopic Hepatocellular Carcinomas in Mice.. Gastroenterology 158(8):2250-2265.e20 PMID: 32060001
- 4. Wang L et al.. 2025. Repression of the ERRγ-CYP2E1 pathway by FGF4 mitigates alcohol-associated liver injury.. Hepatology 82(5):1138-1154 PMID: 40009617
- 5. Gu L et al.. 2023. Fluorofenidone protects against acute liver failure in mice by regulating MKK4/JNK pathway.. Biomed Pharmacother 164:114844 PMID: 37224750
- 6. Lu K et al.. 2024. PDCD4 deficiency in hepatocytes exacerbates nonalcoholic steatohepatitis through enhanced MHC class II transactivator expression.. Metabolism 161:156036 PMID: 39342987
- 7. Sun Q et al.. 2022. SNHG1-miR-186-5p-YY1 feedback loop alleviates hepatic ischemia/reperfusion injury.. Cell Cycle 21(12):1267-1279 PMID: 35275048
- 8. Han Y et al.. 2018. Tumor-Induced Generation of Splenic Erythroblast-like Ter-Cells Promotes Tumor Progression.. Cell 173(3):634-648.e12 PMID: 29606356
